Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases
The corporate venture arms of Eli Lilly and Novartis are backing a $26.1 million round for Charlottesville, VA-based Cavion, a startup focused on a possible key mediator for neurological diseases as well as cancer.
Their drugs target Cav3, which Cavion’s researchers say mediates thalamocortical dysrhythmia, covering a range of diseases such as essential tremor, Parkinson’s disease, neuropathic pain, epilepsy as well as orphan neuro-developmental and genetic disorders such as Angelman Syndrome and Dravet Syndrome.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.